Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
LONDON, April 29, 2024 -- Compass Pathways plc , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Journey Clinical, a leading...
Source: marketscreener.com